Heron Therapeutics, Inc. (HRTX) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Heron Therapeutics, Inc. (HRTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Heron Therapeutics, Inc. (HRTX)

Company Performance

Current Price

as of Oct 18, 2024

$1.76

P/E Ratio

N/A

Market Cap

$266.94M

Description

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Metrics

Overview

HQSan Diego, CA
SectorHealth Technology
IndustryBiotechnology
TickerHRTX
Price$1.76-3.30%

Trading Information

Market Cap$266.94M
Float95.00%
Average Daily Volume (1m)1,544,567
Average Daily Volume (3m)2,129,286
EPS-$0.33

Company

Revenue$136.36M
Rev Growth (1yr)13.42%
Net Income-$9.24M
Gross Margin70.80%
EBITDA Margin-16.11%
EBITDA-$5.80M

EV$644.43M
EV/Revenue4.73
P/EN/A
P/S1.97
P/BN/A

Documents

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-11-14)

Earnings Report (2023-08-14)

Factset

Factset Business Description

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Heron Therapeutics Q3 ($0.54, 0.00) (2023-11-15T08:19:38Z)

Insider transaction: Heron Therapeutics EVP, CFO Ira Duarte discloses purchase of 85K shares - Form 4 ($0.98, +0.06) (2023-11-17T17:39:26Z)

Insider transaction: Heron Therapeutics CEO Craig Collard discloses purchase of 150K shares - Form 4 ($0.98, +0.06) (2023-11-17T17:40:35Z)

Heron Therapeutics reports Q3 EPS ($0.17) vs FactSet ($0.29) [4 est, ($0.33)-(0.23)] ($0.55, 0.00) (2023-11-14T21:11:28Z)